These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32451089)
1. Cognitive function in prostate cancer patients on androgen deprivation therapy: A case-control study. Atallah P; Kanaan RA; Russell N; Allebone J; Grossmann M Gen Hosp Psychiatry; 2020; 67():152-153. PubMed ID: 32451089 [No Abstract] [Full Text] [Related]
2. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients. Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186 [TBL] [Abstract][Full Text] [Related]
3. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? Turco F; Tucci M; Buttigliero C Minerva Urol Nephrol; 2021 Dec; 73(6):870-872. PubMed ID: 35144376 [No Abstract] [Full Text] [Related]
4. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE. Gong J; Posadas EM JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083 [No Abstract] [Full Text] [Related]
5. Factors Associated with Osteoporosis Management Among Veterans Who Received Androgen Deprivation Therapy for Prostate Cancer. Solimeo SL; Lund BC; McCoy KD; Sarrazin MV; Hoffman R J Gen Intern Med; 2021 Oct; 36(10):3270-3272. PubMed ID: 33483816 [No Abstract] [Full Text] [Related]
6. Researchers probe consequences of androgen deprivation for prostate cancer. Friedrich MJ JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787 [No Abstract] [Full Text] [Related]
7. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer. Marzouk S; Naglie G; Tomlinson G; Duff Canning S; Breunis H; Timilshina N; Alibhai SMH J Urol; 2018 Aug; 200(2):327-334. PubMed ID: 29477720 [TBL] [Abstract][Full Text] [Related]
8. Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety. Labban M; Alkassis M; Alkhatib K; Briggs L; Cole AP; Kibel AS; Trinh QD Urol Clin North Am; 2022 May; 49(2):309-321. PubMed ID: 35428436 [TBL] [Abstract][Full Text] [Related]
10. Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity. Lim Fat G; Alibhai S Cancer; 2024 Jun; 130(12):2098-2100. PubMed ID: 38491974 [No Abstract] [Full Text] [Related]
11. The role of intermittent androgen deprivation in prostate cancer. Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079 [No Abstract] [Full Text] [Related]
12. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962 [TBL] [Abstract][Full Text] [Related]
13. Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database. Hatakeyama S; Ohyama C Int J Urol; 2021 May; 28(5):591-592. PubMed ID: 33663016 [No Abstract] [Full Text] [Related]
15. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy. Chan JSK; Lee YHA; Liu K; Hui JMH; Dee EC; Ng K; Satti DI; Tang P; Tse G; Ng CF Eur J Clin Invest; 2023 Apr; 53(4):e13932. PubMed ID: 36468787 [No Abstract] [Full Text] [Related]
16. Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels. Saad F Eur Urol; 2015 May; 67(5):837-8. PubMed ID: 25168615 [No Abstract] [Full Text] [Related]
17. Prostate cancer treated with androgen deprivation therapy has consequences for bone. Adler RA Endocrine; 2014 Apr; 45(3):339-40. PubMed ID: 24366636 [No Abstract] [Full Text] [Related]
18. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Kwon DH; Vashisht R; Borno HT; Aggarwal RR; Small EJ; Butte AJ; Huang FW Ann Oncol; 2021 May; 32(5):678-679. PubMed ID: 33571636 [No Abstract] [Full Text] [Related]
19. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178 [TBL] [Abstract][Full Text] [Related]
20. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? Saylor PJ; Fogerty AE Lancet Oncol; 2010 May; 11(5):406-7. PubMed ID: 20395175 [No Abstract] [Full Text] [Related] [Next] [New Search]